Patient-Reported Outcome Of Facial Erythema (PROOF)

NCT01885000 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Rosacea
Erythema

Interventions

DRUG: Brimonidine tartrate was applied cutaneously once daily for 8 days.
DRUG: Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.

Sponsor

Galderma R&D